Complete title: An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies
| Research Study Number | 9847 |
| Principal Investigator | Damian Green, MD |
| Phase | II |
Other eligibility criteria may apply.
| Research Study Number | 9847 |
| Contact | Seattle Cancer Care Alliance Intake Office |
| Telephone | 800-804-8824 / 206-606-1024 |
Keywords: Leukemia, Chronic Lymphocytic (CLL); Hematologic Malignancies; Leukemia; Lymphoma; Lymphoproliferative Disorders; Multiple Myeloma (MM); Lymphoma, Non-Hodgkin (NHL); Leukemia, Lymphoid; Immunoproliferative Disorders; Waldenstrom Macroglobulinemia; Lymphoma, Mantle-Cell; Cardiovascular Diseases; Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Small Lymphocytic (SLL); Leukemia, Lymphocytic, Chronic, B-Cell; Paraproteinemias; Lymphoma, Large B-Cell, Diffuse; Immune System Diseases; Hemostatic Disorders; Lymphoma, Marginal Zone
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.